Atazanavir is known as Reyataz in the US. The deal is a non-exclusive agreement and the companies were selected through an international bidding process. The arrangement includes the transfer of technology dealing with the manufacture, testing, packaging, storage and handling of the drug's active ingredient. The drug is a second line antiretroviral for patients who have developed a resistance to more common drugs. Peter Dolan, the chief executive of BMS, said the company has taken a broad-based approach to addressing the Aids crisis, which included providing Aids medicines at no-profit prices.
Source: Business Report
